Skip to main content
. 2019 Oct 1;12(10):29–34.

TABLE 2.

Topical antifungals treatments

DRUG NAME (TRADE NAME) REGIMEN STRUCTURE MECHANISM OF ACTION MOLECULAR WEIGHT (G/MOL) REPORTED CURE RATE (%)
Tavaborole (Kerydin) Solution applied daily for 48 weeks graphic file with name jcad_12_10_29_g001.jpg Inhibition of fungal protein synthesis by binding to cytoplasmic leucyl-tRNA 151.93 Mycologic: 30–36
Complete: 6–10
Efinaconazole
(Jublia)		 Solution applied daily for 48 weeks graphic file with name jcad_12_10_29_g002.jpg Blocking of ergosterol synthesis by inhibition of lanosterol 14-α-demethylase 348.39 Mycologic: 53.4–55.2
Complete: 15.2–17.8
Ciclopirox
(Penlac)		 Nail lacquer
Debridement + daily application		 graphic file with name jcad_12_10_29_g003.jpg Chelation of metal cations needed as enzyme cofactors
Modification of fungal plasma membrane of fungi		 207.27 Mycologic: 29–36
Complete: 5.5–8.5
ME 1111 TBD graphic file with name jcad_12_10_29_g004.jpg Targeting of fungal electron transport chain at complex II 202.25 TBD
Auriclosene TBD graphic file with name jcad_12_10_29_g005.jpg Protein inactivation via modification of sulfur-containing amino acids 222.08 TBD
Luliconazole TBD graphic file with name jcad_12_10_29_g006.jpg Inhibition of ergosterol synthesis
Inhibition of extracellular protease secretion		 354.28 Mycologic: 53.4–55.2
Complete: 14.9

TBD: To be determined